The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha.
lenalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein] CRBN results in increased susceptibility to lenalidomide lenalidomide binds to [CRBN protein binds to DDB1 protein]; lenalidomide binds to [SALL4 protein binds to CRBN protein]
[Dexamethasone co-treated with Lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with Lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein; [Dexamethasone co-treated with Lenalidomide] results in increased expression of F3 mRNA; [Dexamethasone co-treated with Lenalidomide] results in increased expression of F3 protein
lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1B mRNA] Lenalidomide inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
Lenalidomide inhibits the reaction [Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]]
lenalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]
lenalidomide binds to [SALL4 protein binds to CRBN protein] lenalidomide results in increased degradation of and results in decreased expression of SALL4 protein
lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1A mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1B mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]; lenalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]; lenalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]
lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA] Lenalidomide inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of TNF protein]